FDA Refuses to Review Moderna's Experimental Flu Shot Application

Moderna announced that the U.S. Food and Drug Administration (FDA) has refused to review its application for the experimental influenza shot, mRNA-1010. The pharmaceutical giant described the FDA's decision as inconsistent with prior feedback regarding the investigational vaccine. This unexpected refusal introduces significant uncertainty and potential delays in the product's regulatory pathway and commercialization timeline. Analysts suggest this could negatively impact Moderna's future revenue prospects and investor sentiment. The decision raises questions about the development trajectory of Moderna's broader mRNA vaccine pipeline beyond COVID-19.